(Q84371754)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Alemtuzumab versus interferon beta-1a in early multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Dennis Bourdette

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Vijayshree Yadav

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

Current Neurology and Neuroscience Reports

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

341-342

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19664362%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11910-009-0062-1

5 February 2020

exact match

0 references

cites work

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

1 reference

12 December 2020

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Alemtuzumab in chronic lymphocytic leukemia

1 reference

12 December 2020

Daclizumab in treatment of multiple sclerosis patients

1 reference

12 December 2020

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

12 December 2020